STAT
AUGUST 20, 2024
Last week, a mask ban in Nassau County, New York was signed into law. If I lived just 60 miles east of my New Jersey town, I would be under threat of a fine or jail time every time I left the house. I’ve been masking consistently in public since 2020, when the Covid-19 pandemic began, because I have a kidney transplant and will take immunosuppressant medication for the rest of my life.
Fierce Healthcare
AUGUST 20, 2024
Health IT giant Epic is pushing ahead rapidly to build out artificial intelligence technologies and generative AI features in its electronic health record software. | The goal, according to Epic executives, is to ease the documentation burden for clinicians, streamline charting and coding and bring evidence-based medical insights and research right to doctors' fingertips at the point of care.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
AUGUST 20, 2024
Eli Lilly’s obesity drug Zepbound significantly cut the risk of developing type 2 diabetes, showing the benefits of long-term use of the blockbuster therapy. In a Phase 3 trial that lasted over three years, people with pre-diabetes taking Zepbound had a 93% lower risk of progressing to diabetes compared with people on placebo, Lilly said Tuesday.
Fierce Pharma
AUGUST 20, 2024
Regulators in both the U.S. and Europe have looked into the potential link between suicidal thoughts and Novo Nordisk’s blockbuster semaglutide franchise after reports sounded the alarm last year. | Researchers found that users of Novo's semaglutide who were logged in a WHO database were more likely to report suicidal ideation.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT
AUGUST 20, 2024
A new observational study found that people taking Ozempic and Wegovy appeared to experience suicidal thoughts at a higher rate than people on other drugs, though experts raised concerns about the methodology and the findings contradict what some other studies have found about the class of GLP-1 diabetes and obesity drugs. Academic researchers analyzed a World Health Organization database that tracks suspected adverse drug reactions, and found that there was a 45% greater rate of reports of suic
Fierce Pharma
AUGUST 20, 2024
As House lawmakers prepare for a September vote on the controversial BIOSECURE Act, the House Select Committee on the CCP is expanding the scope of its scrutiny on China's biopharma ecosystem. | As House lawmakers prepare for a September vote on the controversial BIOSECURE Act, the House Select Committee on the CCP is expanding the scope of its scrutiny on China's biopharma ecosystem.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
AUGUST 20, 2024
The upward trajectory of Medicare Advantage (MA) enrollment is likely to become an issue for hospitals and other healthcare providers forced to contend with plans’ prior authorization requirements | Prior authorization burdens and "a challenging contract negotiation season" on the horizon are likely headwinds for providers, and hospitals in particular, according to a recent report.
STAT
AUGUST 20, 2024
Next week, the biopharma world will see eagerly awaited results from a trial that could shape care for patients with an increasingly common heart condition — and determine which companies stand to reap billions. The trial of vutrisiran, from Alnylam Pharmaceuticals, was already announced as positive , with the drug successfully cutting the risk of death and cardiovascular complications in patients with the disease, called transthyretin amyloid cardiomyopathy, or ATTR-CM.
Fierce Pharma
AUGUST 20, 2024
Already wildly popular in type 2 diabetes and obesity, Eli Lilly’s tirzepatide can help prevent one of the very diseases it’s meant to treat, new data show. | Already wildly popular in type 2 diabetes and obesity, Eli Lilly’s tirzepatide can help prevent one of the very diseases it’s meant to treat, new data show.
STAT
AUGUST 20, 2024
Science is a team sport, and those teams are getting larger. While that expansion might help researchers answer complex biomedical questions by working together, a recent study suggests that this trend has hampered the career prospects of Ph.D. graduates. The authors analyzed 40 years of data from a National Science Foundation survey that tracks Ph.D. graduates.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Pharma
AUGUST 20, 2024
A new FDA approval has vaulted a Johnson & Johnson lung cancer drug combination into a key territory already dominated by AstraZeneca’s Tagrisso. | A new FDA approval has vaulted a Johnson & Johnson lung cancer drug combination into a key territory already dominated by AstraZeneca’s Tagrisso. But the real battle against the EGFR king has yet to start.
STAT
AUGUST 20, 2024
The Food and Drug Administration’s responsibilities don’t end when a drug hits the market after it’s approved: the agency is also continuously assessing products after they’re widely available for any safety issues. And a group of researchers — including two from the FDA’s Center for Drug Evaluation and Research — think artificial intelligence could uncover more signs of these issues, including from electronic health records, social media posts, a
Fierce Healthcare
AUGUST 20, 2024
Employers are up against escalating healthcare costs, driven by mounting prescription drug expenses, inflation and worsening chronic conditions, a new survey shows. | Employers are up against escalating healthcare costs, driven by mounting prescription drug expenses, inflation and worsening chronic conditions, a new survey shows.
Pharmacy Times
AUGUST 20, 2024
The breakthrough therapy designation was granted based on ongoing data from the ARTEMIS-001 phase 1 open-label, multi-center trial.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Pharma
AUGUST 20, 2024
For years, Teva has been defending itself against allegations that it used illegal Medicare co-pay schemes to fuel sales of its multiple sclerosis drug Copaxone. | The new lawsuit, filed in a Kansas court, comes as Teva defends against similar allegations made by the U.S. government.
pharmaphorum
AUGUST 20, 2024
Learn about the exciting potential of CDK9 inhibitors in disrupting cancer cell growth and changing the treatment landscape for cancer patients. Stay updated on the latest research and developments in this promising field.
Pharmacy Times
AUGUST 20, 2024
The combination is the first and only multi-targeted chemotherapy-free regimen that demonstrated superiority compared with osimertinib for non–small cell lung cancer (NSCLC).
STAT
AUGUST 20, 2024
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Hello and happy Tuesday! Our intrepid First Opinion editor Torie Bosch is back, and she has some big ideas for the section in the coming months.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Healthcare
AUGUST 20, 2024
Amid significant scrutiny from lawmakers and regulators on Medicare Advantage, a new report suggests that consumer satisfaction with these plans is notably higher than with commercial insurance.
pharmaphorum
AUGUST 20, 2024
Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese adults with pre-diabetes.There's plenty of evidence to show that prediabetes – a higher-than-normal blood sugar level resulting from a level of insulin resistance that isn't high enough to be considered full-blown diabetes – can be reversed if patients commit to an intensive regimen of dietary restriction
STAT
AUGUST 20, 2024
Rise and shine, everyone, another busy day is on the way. We can tell because the pace of motor vehicles passing by our window is picking up and the official mascots are busy foraging for their breakfast on the campus grounds. As for us, we are engaged in the usual ritual of brewing cups of stimulation. Our choice today is maple bourbon. Yes, this is real.
pharmaphorum
AUGUST 20, 2024
Emergent BioSolutions has agreed to donate 50,000 doses of its mpox vaccine for use in the current outbreak, but an expert has warned supplies are unlikely to meet demand
Pharmacy Times
AUGUST 20, 2024
Vimseltinib (Deciphera Pharmaceuticals) has a Prescription Drug User Fee Act goal date of February 17, 2025.
Fierce Healthcare
AUGUST 20, 2024
Below is a roundup of payer-centric news headlines you may have missed during the month of August 2024. | This month, Devoted Health completed its series E funding round, L.A. Care Health Plan slashed prior auth codes for catheter supplies, and Illinois signed laws cracking down on insurers involving colonoscopies, inhalers and more.
Pharmaceutical Technology
AUGUST 20, 2024
The top 20 biopharmaceutical companies demonstrated resilience during the second quarter (Q2) of 2024 as global markets and investor optimism improved with anticipation of a potential interest rate cut from the US Federal Reserve.
STAT
AUGUST 20, 2024
Off-patent medicines provide people with access to high-quality essential treatment options that can be significantly less expensive than branded on-patent medicines. Off-patent therapies — generics and biosimilars — represent a system-critical industry that delivers around 80% of medicines used worldwide at a fraction of the cost of branded medicines.
Pharmacy Times
AUGUST 20, 2024
Jasmine Perry discusses the More Than a Script program in an interview with Pharmacy Times.
pharmaphorum
AUGUST 20, 2024
Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in various forms of cancer.Copenhagen-based Adcendo is paying what is rumours to be tens of millions of dollars in upfront fees for rights to Multitude's anti-tissue factor (TF) ADC AMT-754 – now renamed ADCE-T02 – outside mainland China, Hong Kong, Macau, and Taiwan.
Drug Topics
AUGUST 20, 2024
Bipartisan support—in a polarized Congress—underscores the importance of pharmacy benefit manager reform.
STAT
AUGUST 20, 2024
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Carbon Health founder steps back from top role Carbon Health ‘ s chief executive and co-founder Eren Bali is taking a step back from the primary care tech company, returning instead to the education company Udemy he co-founded as its chief technology office
Pharmacy Times
AUGUST 20, 2024
Palliative pharmacists are invaluable assets of oncologic care.
The Checkup by Singlecare
AUGUST 20, 2024
Vyvanse is the branded version of the drug lisdexamfetamine dimesylate. The U.S. Food and Drug Administration (FDA) has approved it as a prescription medication for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients older than six years. It’s also approved for binge-eating disorder ( BED ) in adult patients but is typically used as a second-line therapy.
Outsourcing Pharma
AUGUST 20, 2024
The Danish company Bavarian Nordic plans to supply up to 2 million vaccine doses this year in response to the World Health Organizationâs declaration of mpox as a Public Health Emergency of International Concern (PHEIC) earlier this month.
Expert insights. Personalized for you.
145 
Let's personalize your content